Cargando…
iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome
Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539496/ https://www.ncbi.nlm.nih.gov/pubmed/37770589 http://dx.doi.org/10.1038/s42003-023-05203-4 |
_version_ | 1785113511665336320 |
---|---|
author | Hirayama, Ryuichiro Toyohara, Kosuke Watanabe, Kei Otsuki, Takeya Araoka, Toshikazu Mae, Shin-Ichi Horinouchi, Tomoko Yamamura, Tomohiko Okita, Keisuke Hotta, Akitsu Iijima, Kazumoto Nozu, Kandai Osafune, Kenji |
author_facet | Hirayama, Ryuichiro Toyohara, Kosuke Watanabe, Kei Otsuki, Takeya Araoka, Toshikazu Mae, Shin-Ichi Horinouchi, Tomoko Yamamura, Tomohiko Okita, Keisuke Hotta, Akitsu Iijima, Kazumoto Nozu, Kandai Osafune, Kenji |
author_sort | Hirayama, Ryuichiro |
collection | PubMed |
description | Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering drug discovery is the absence of effective in vitro methods for testing the restoration of normal GBMs. Here, we aimed to develop kidney organoid models from AS patient iPSCs for this purpose. We established iPSC-derived collagen α5(IV)-expressing kidney organoids and confirmed that kidney organoids from COL4A5 mutation-corrected iPSCs restore collagen α5(IV) protein expression. Importantly, our model recapitulates the differences in collagen composition between iPSC-derived kidney organoids from mild and severe AS cases. Furthermore, we demonstrate that a chemical chaperone, 4-phenyl butyric acid, has the potential to correct GBM abnormalities in kidney organoids showing mild AS phenotypes. This iPSC-derived kidney organoid model will contribute to drug discovery for AS. |
format | Online Article Text |
id | pubmed-10539496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-105394962023-09-30 iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome Hirayama, Ryuichiro Toyohara, Kosuke Watanabe, Kei Otsuki, Takeya Araoka, Toshikazu Mae, Shin-Ichi Horinouchi, Tomoko Yamamura, Tomohiko Okita, Keisuke Hotta, Akitsu Iijima, Kazumoto Nozu, Kandai Osafune, Kenji Commun Biol Article Alport syndrome (AS) is a hereditary glomerulonephritis caused by COL4A3, COL4A4 or COL4A5 gene mutations and characterized by abnormalities of glomerular basement membranes (GBMs). Due to a lack of curative treatments, the condition proceeds to end-stage renal disease even in adolescents. Hampering drug discovery is the absence of effective in vitro methods for testing the restoration of normal GBMs. Here, we aimed to develop kidney organoid models from AS patient iPSCs for this purpose. We established iPSC-derived collagen α5(IV)-expressing kidney organoids and confirmed that kidney organoids from COL4A5 mutation-corrected iPSCs restore collagen α5(IV) protein expression. Importantly, our model recapitulates the differences in collagen composition between iPSC-derived kidney organoids from mild and severe AS cases. Furthermore, we demonstrate that a chemical chaperone, 4-phenyl butyric acid, has the potential to correct GBM abnormalities in kidney organoids showing mild AS phenotypes. This iPSC-derived kidney organoid model will contribute to drug discovery for AS. Nature Publishing Group UK 2023-09-28 /pmc/articles/PMC10539496/ /pubmed/37770589 http://dx.doi.org/10.1038/s42003-023-05203-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hirayama, Ryuichiro Toyohara, Kosuke Watanabe, Kei Otsuki, Takeya Araoka, Toshikazu Mae, Shin-Ichi Horinouchi, Tomoko Yamamura, Tomohiko Okita, Keisuke Hotta, Akitsu Iijima, Kazumoto Nozu, Kandai Osafune, Kenji iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title | iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title_full | iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title_fullStr | iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title_full_unstemmed | iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title_short | iPSC-derived type IV collagen α5-expressing kidney organoids model Alport syndrome |
title_sort | ipsc-derived type iv collagen α5-expressing kidney organoids model alport syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539496/ https://www.ncbi.nlm.nih.gov/pubmed/37770589 http://dx.doi.org/10.1038/s42003-023-05203-4 |
work_keys_str_mv | AT hirayamaryuichiro ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT toyoharakosuke ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT watanabekei ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT otsukitakeya ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT araokatoshikazu ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT maeshinichi ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT horinouchitomoko ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT yamamuratomohiko ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT okitakeisuke ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT hottaakitsu ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT iijimakazumoto ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT nozukandai ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome AT osafunekenji ipscderivedtypeivcollagena5expressingkidneyorganoidsmodelalportsyndrome |